Vanguard (NYSE) reports 0 shares in Syndax after realignment (SNDX)
Rhea-AI Filing Summary
Syndax Pharmaceuticals Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 causing certain Vanguard subsidiaries to report holdings separately.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings and reports no beneficial ownership in Syndax.
The filing states 0 shares and 0% beneficial ownership as reported by The Vanguard Group following an internal realignment. The disclosure cites January 12, 2026 and SEC Release No. 34-39538 for the change in reporting treatment.
Cash-flow treatment and any subsidiary holdings are not provided in this excerpt; subsequent filings by Vanguard subsidiaries may list holdings separately.